TherapeuticsMD (TXMD) Research & Development (2011 - 2022)

TherapeuticsMD has reported Research & Development for 12 years, with the latest figure at $1.1 million in Q3 2022.

• For the quarter ending Q3 2022, Research & Development fell 30.72% year-over-year to $1.1 million; the trailing twelve-month figure through Sep 2022 stood at $5.5 million (down 31.61% YoY), and the FY2021 full-year result was $7.1 million, down 32.07% from the prior year.
• Research & Development for Q3 2022 stood at $1.1 million, down from $1.6 million in the prior quarter.
• The five-year high for Research & Development was $7.0 million in Q1 2018, with the low at $1.1 million in Q3 2022.
• Historically, Research & Development has averaged $3.6 million across 5 years, with a median of $2.7 million in 2020.
• Annual changes were most pronounced in 2018 — Research & Development increased 4.22% — and 2020, when it slumped 50.29%.
• TherapeuticsMD's Research & Development stood at $6.8 million in 2018, then tumbled by 34.37% to $4.4 million in 2019, then slumped by 45.98% to $2.4 million in 2020, then sank by 40.69% to $1.4 million in 2021, then dropped by 21.69% to $1.1 million in 2022.
• The last three Research & Development figures came in at $1.1 million (Q3 2022), $1.6 million (Q2 2022), and $1.4 million (Q1 2022), per Business Quant data.